Predicting Factors for Oncological and Functional Outcome in Hypopharyngeal Cancer.


Journal

The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378

Informations de publication

Date de publication:
05 2021
Historique:
revised: 31 08 2020
received: 01 07 2020
accepted: 05 10 2020
pubmed: 25 10 2020
medline: 8 5 2021
entrez: 24 10 2020
Statut: ppublish

Résumé

Hypopharyngeal squamous cell carcinoma (SCC) is a rare but aggressive malignancy, with low survival rates and high incidence of tumor and treatment-related morbidity. This study aims to analyze the long-term oncologic and functional outcomes of a large cohort of patients and to determine prognostic factors. Retrospective cohort study. The records of all patients diagnosed with hypopharyngeal SCC and treated with curative intent at our tertiary referral center were reviewed. Patient and initial disease characteristics, features, and complications of primary treatment, recurrence patterns, and corresponding treatments and the oncologic and functional long-term outcome were determined. For a total of 179 patients, primary radiotherapy (RT) was the predominant treatment modality (78%), whereas 22% underwent primary surgery. The median, 2-year, and 5-year overall survival (OS) for the study cohort were 47 months, 64% and 43%. The median survival after first and second relapse was 7 and 6 months, respectively. The 2 and 5-year relapse-free survival (RFS) was 52% and 36%. The median RFS after first relapse and salvage treatment was 9 months. A nodal status of ≥cN2 (HR = 1.89, CI:1.21-3.05, P < .005) and any other primary tumor localization than pyriform sinus (HR = 1.60, CI: 1.04-2.42, P < .05) were identified as independent risk factors for shorter OS and RFS. Regarding functional outcome, the 2- and 5-year laryngectomy-free-survival was 55% and 37%, respectively. In this large cohort with long-term follow-up, any other primary tumor localization than pyriform sinus and a nodal status of ≥cN2 were identified as risk factors for reduced OS and RFS. 4 Laryngoscope, 131:E1543-E1549, 2021.

Identifiants

pubmed: 33098325
doi: 10.1002/lary.29186
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

E1543-E1549

Informations de copyright

© 2020 American Laryngological, Rhinological and Otological Society Inc, "The Triological Society" and American Laryngological Association (ALA).

Références

Habib A. Management of advanced hypopharyngeal carcinoma: systematic review of survival following surgical and non-surgical treatments. J Laryngol Otol 2018;132:385-400.
Hung L-T, Huang H-I, Wang L-W, Yang M-H, Chu P-Y. Oncologic results and quality of life in patients with squamous cell carcinoma of hypopharynx after transoral laser microsurgery. Lasers Surg Med 2017;50:117-124.
Kim S-Y, Rho Y-S, Choi E-C, et al. Clinicopathological factors influencing the outcomes of surgical treatment in patients with T4a hypopharyngeal cancer. BMC Cancer 2017;17:904.
Lim SH, Lee SJ, Ahn M-J, Park K, Sun J-M. Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: implication for subgroup selection for induction chemotherapy. Jpn J Clin Oncol 2015;46:40-45.
Takes RP, Strojan P, Silver CE, et al. Current trends in initial management of hypopharyngeal cancer: the declining use of open surgery. Head Neck 2010;34:270-281.
Lefebvre J-L, Andry G, Chevalier D, et al. Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. Ann Oncol 2012;23:2708-2714.
Janoray G, Pointreau Y, Garaud P, et al. Long-term results of a multicenter randomized phase III trial of induction chemotherapy with Cisplatin, 5-fluorouracil, ± Docetaxel for larynx preservation. JNCI: J Natl Cancer Inst 2015;108:djv368. https://doi.org/10.1093/jnci/djv368.
Joo Y-H, Cho K-J, Park J-O, Nam I-C, Kim M-S. Role of larynx-preserving partial hypopharyngectomy with and without postoperative radiotherapy for squamous cell carcinoma of the hypopharynx. Oral Oncol 2012;48:168-172.
Bhayani MK, Hutcheson KA, Barringer DA, Roberts DB, Lewin JS, Lai SY. Gastrostomy tube placement in patients with hypopharyngeal cancer treated with radiotherapy or chemoradiotherapy: factors affecting placement and dependence. Head Neck 2013;35:1641-1646.
Chen AM, Hsu S, Meshman J, et al. Effect of daily fraction size on laryngoesophageal dysfunction after chemoradiation for squamous cell carcinomas of the larynx and hypopharynx. Head Neck 2017;39:1322-1326.
Hall SF, Groome PA, Irish J, O'Sullivan B. The natural history of patients with squamous cell carcinoma of the Hypopharynx. Laryngoscope 2008;118:1362-1371.
Taguchi T, Nishimura G, Takahashi M, et al. Treatment results and prognostic factors for advanced squamous cell carcinoma of the hypopharynx treated with concurrent chemoradiotherapy. Cancer Chemother Pharmacol 2014;73:1147-1154.
Thariat J, Ang KK, Allen PK, et al. Prediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinoma. Int J Rad Oncol Biol Phys 2012;82:e367-e374.
Anschuetz L, Shelan M, Dematté M, Schubert AD, Giger R, Elicin O. Long-term functional outcome after laryngeal cancer treatment. Radiat Oncol 2019;14:101.
Anschuetz L, Visini M, Shelan M, Elicin O, Giger R. Risk analysis for tracheostomy dependency in curatively treated laryngeal cancer with organ preservation. Head Neck 2018;40:2469-2475.
Hoffman HT, Karnell LH, Shah JP, et al. Hypopharyngeal cancer patient care evaluation. Laryngoscope 1997;107:1005-1017.
Petersen JF, Arends CR, van der Noort V, et al. Laryngo-esophageal dysfunction free survival and propensity score matched analysis comparing organ preservation and total laryngectomy in hypopharynx cancer. Oral Oncol 2019;95:143-149.
Vourexakis Z, Janot F, Dulguerov P, Le Ridant A-M. Larynx preservation protocols: long-term functional outcomes in good responders to induction chemotherapy for Pyriform sinus carcinoma. ORL 2014;76:165-170.

Auteurs

Miranda Visini (M)

Department of Otorhinolaryngology, Head and Neck Surgery, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.

Roland Giger (R)

Department of Otorhinolaryngology, Head and Neck Surgery, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.

Mohamed Shelan (M)

Department of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.

Olgun Elicin (O)

Department of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.

Lukas Anschuetz (L)

Department of Otorhinolaryngology, Head and Neck Surgery, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH